To read the full story
Related Article
- Takeda to Offload TachoSil to Corza Health
September 17, 2020
- Takeda to See US$200 Million Operating Loss Tied to Novartis' EU Xiidra Withdrawal
June 30, 2020
- J&J’s TachoSil Deal Dropped on Antitrust Issues; Takeda Mum on Future Plan
April 16, 2020
- Takeda to Divest Non-Core Assets Sold in Russia, Former Soviet States
November 6, 2019
- Takeda to Divest 30 OTC, Non-Core Assets to Swiss Firm
October 16, 2019
- Takeda Completes Divestment of Dry Eye Drug Xiidra to Novartis
July 3, 2019
BUSINESS
- Nipro’s Stemirac Clinches Full Approval in Japan
November 17, 2026
- Kyorin Bags Japan Rights to Acadia’s Rett Syndrome Drug
November 17, 2026
- Eisai, J&J, Takeda among Firms Rolling Out Newly Listed Medicines in Japan
November 16, 2026
- Fuji Poised to Hit 10 Billion Yen Biosimilar Sales Mark, Led by Eylea Follow-On
November 16, 2026
- Seikagaku Sees Over a Year Before US Refiling of Herniated Disk Drug
November 16, 2026
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…





